A cannabis-derived medicine for chronic low back pain has moved closer to a possible U.S. regulatory pathway after the Food and Drug Administration granted Breakthrough Therapy Designation to VER-01, an investigational full-spectrum Cannabis sativa extract developed by German pharmaceutical company Vertanical. The designation, announced May 18, 2026, was supported by two randomized Phase 3 trials that found the drug reduced pain while improving several related outcomes, including sleep and physical function. One study compared VER-01 with placebo, while a second tested the medicine directly against conventional opioid treatment.
The development stands out because cannabis-based treatments for chronic pain have long occupied an unusual medical position: commonly used by patients but supported by research involving widely varying products, doses and study designs. VER-01 is different from dispensary cannabis or a generic THC tincture. It is a pharmaceutical-grade botanical medicine manufactured to deliver a reproducible chemical composition. However, the FDA designation does not mean VER-01 is approved in the United States. Additional American clinical testing remains underway before Vertanical can seek marketing approval.
What FDA Breakthrough Therapy Designation Actually Means
The FDA’s Breakthrough Therapy program is intended to accelerate development and review of investigational medicines for serious conditions when preliminary clinical evidence indicates that a drug may offer a substantial improvement over available treatments on a clinically significant endpoint. A designated medicine can receive more intensive FDA guidance and access to features associated with the agency’s Fast Track program, potentially allowing important questions about study design, manufacturing and clinical evidence to be addressed more efficiently.
The word “breakthrough” can nevertheless be misleading when interpreted as an approval. The designation does not establish that VER-01 has already been proven safe and effective enough for the U.S. market, nor does it amount to an endorsement of cannabis products generally. Vertanical says the FDA designation was supported by its European Phase 3 program. The company has since begun an additional pivotal U.S. Phase 3 study, with a first data readout expected in 2027 and a potential New Drug Application planned for 2028 if the results are successful.
What Is VER-01?
VER-01, marketed under the name Exilby in Germany, is made from a proprietary Cannabis sativa variety called DKJ127 L. Unlike medicines containing only purified CBD or a synthetic cannabinoid, it is a standardized full-spectrum extract containing several cannabis compounds. Each dose unit used in the pivotal trial contained 2.5 milligrams of THC, 0.1 milligrams of cannabigerol, or CBG, and 0.02 milligrams of CBD. The preparation also contains terpenes, flavonoids, phytosterols and other constituents and is manufactured under pharmaceutical Good Manufacturing Practice conditions.
Patients take VER-01 orally and gradually adjust the amount according to symptom relief and tolerability. The Phase 3 protocol allowed doses to increase every three days up to 13 dose units daily. Although its combination of cannabinoids and other plant chemicals raises questions about interactions between multiple cannabis constituents, the research did not establish that an “entourage effect” explains the results. More importantly, the investigators emphasize that findings involving VER-01 cannot automatically be applied to smoked marijuana, dispensary oils, CBD products or other cannabis extracts because their chemical compositions may be substantially different.
The Large Placebo-Controlled Phase 3 Trial
The most rigorous evidence supporting VER-01 comes from a multicenter Phase 3 trial published in Nature Medicine in September 2025. Researchers enrolled 820 adults with chronic nonspecific low back pain, most of whom had already tried analgesic treatment without adequate success. Participants were randomly assigned to VER-01 or placebo in a double-blind study that included a three-week dose-titration period followed by 12 weeks of treatment. Average pain at the beginning of the study was approximately six points on an 11-point numerical scale.
VER-01 met the trial’s primary endpoint. Average pain declined by 1.9 points from baseline among patients taking VER-01 compared with 1.4 points with placebo, an adjusted difference of 0.6 points. The average advantage was therefore real but relatively modest. Responder rates were more striking: 54.1 percent of VER-01 patients experienced at least a 30 percent reduction in pain compared with 39.5 percent receiving placebo, while 32.2 percent versus 22.8 percent achieved at least a 50 percent reduction. Patients taking VER-01 also required less rescue medication and reported greater improvements in sleep and physical functioning. Among participants with neuropathic pain characteristics, the difference in pain reduction compared with placebo increased to 1.5 points.
VER-01 Was Also Tested Directly Against Opioids
A second Phase 3 trial published in Pain and Therapy enrolled 384 adults and randomly assigned them to VER-01 or conventional opioid treatment. This trial was open-label rather than blinded and was structured to resemble ordinary clinical practice, allowing doctors to select and modify opioid therapy according to individual patient needs. Following titration, treatment continued for approximately six months. Importantly, the trial’s primary endpoint was not pain reduction; it was gastrointestinal tolerability, measured primarily through the development of constipation.
VER-01 performed substantially better on that outcome. Patients receiving it had roughly one-quarter the risk of developing treatment-emergent constipation compared with those receiving opioids, while 5.8 percent of VER-01 patients required laxatives compared with 17.2 percent in the opioid group. Pain scores also favored VER-01 when analyzed across the treatment period. Average pain fell 2.33 points with VER-01 versus 1.89 with opioids over 12 weeks and 2.50 versus 2.16 across six months. Sleep interference also improved more with VER-01. However, the absolute differences in pain were small, some secondary endpoints assessed specifically at the final treatment week did not reach statistical significance, and the lack of blinding creates the possibility that expectations influenced patient-reported outcomes.
Why These Findings Are Important for Cannabis Research
The results are notable because earlier research on cannabinoids for chronic pain has generally produced a more cautious picture. A 2024 BMJ Open systematic review and network meta-analysis examined 90 randomized trials involving 22,028 patients with chronic non-cancer pain. Researchers concluded that both opioids and medical cannabis produced relatively small improvements in pain, physical functioning and sleep compared with placebo. Low-certainty evidence suggested little difference between cannabis and opioids for pain relief, although cannabis treatments resulted in fewer discontinuations caused by adverse events.
A 2025 systematic review of cannabis-based medicines for neuropathic pain also found mixed results. Fifteen of 22 randomized trials reported significant pain reductions, while seven failed to demonstrate significant benefit over placebo. The authors pointed to small sample sizes, short study durations, inconsistent formulations and potential unblinding from THC’s recognizable effects as persistent problems in the evidence base. VER-01 addresses some of those weaknesses by using a standardized formulation and much larger Phase 3 populations. Its particularly strong results among patients with neuropathic characteristics may also prove clinically important, although additional studies are required to confirm which groups are most likely to benefit.
Safety and Dependence Require a Closer Look
The trials do not show that VER-01 is free of adverse effects. During the placebo-controlled Phase 3 study, 83.3 percent of VER-01 recipients experienced treatment-emergent adverse events compared with 67.3 percent receiving placebo. Dizziness was particularly common, occurring in 42.8 percent of the VER-01 group versus 5.2 percent of placebo recipients. Nausea, fatigue, dry mouth and sleepiness were also increased, and 17.3 percent of patients stopped VER-01 because of adverse events compared with 3.5 percent taking placebo. Most events were considered mild or moderate, while serious adverse-event rates were similar between the two groups.
Researchers reported no evidence of drug abuse, dependence or cannabis withdrawal during the study program, including after abrupt discontinuation among patients evaluated for withdrawal. That finding could become one of VER-01’s most significant advantages if confirmed in broader populations, particularly when compared with opioids. Still, it should not be interpreted as evidence that THC can never cause dependence or withdrawal. The placebo trial excluded people with histories of drug or medication abuse and certain severe psychiatric illnesses, and formal cognitive testing was not performed. Investigators also acknowledged that participants were not formally asked whether they had guessed their treatment assignment.
Germany Has Already Authorized Exilby
VER-01 has meanwhile crossed a regulatory threshold in Europe. On June 9, 2026, Vertanical announced that Germany had granted marketing authorization for Exilby in patients with chronic low back pain involving a radicular, or neuropathic, component. The authorization followed the two Phase 3 studies involving more than 1,200 participants combined. The German indication is particularly noteworthy because the subgroup with neuropathic pain showed some of the largest benefits in the clinical program.
The situation remains different in the United States. Exilby is not FDA-approved, and the additional pivotal U.S. trial is intended to satisfy American regulatory requirements. Breakthrough Therapy status should provide Vertanical with closer interaction with FDA during that process, but approval will ultimately depend on whether the complete evidence demonstrates that benefits outweigh risks for the proposed patient population.
Could a Cannabis Medicine Become an Alternative to Opioids?
VER-01 may ultimately be important not because it proves that “marijuana works for back pain,” but because it demonstrates what cannabis-derived medicine can look like when a botanical product is chemically standardized and subjected to conventional late-stage pharmaceutical testing. The placebo-controlled evidence shows a statistically significant benefit, while the head-to-head trial suggests the drug may offer comparable or slightly greater pain relief with substantially less constipation than opioids. Stable dosing during longer treatment and the absence of observed withdrawal signals are also encouraging findings that warrant continued investigation.
There are still unanswered questions. The average improvement over placebo was modest, cognitive effects were not formally measured, some patient populations were excluded, and the opioid comparison was open-label. Longer and independent studies will be important for establishing durability, dependence risk and real-world effectiveness. Nevertheless, FDA Breakthrough Therapy Designation represents a significant regulatory milestone for a cannabis-derived pain medicine. If the U.S. Phase 3 program confirms the European findings, VER-01 could become one of the clearest examples yet of cannabis moving from broadly defined medical use toward precisely manufactured, indication-specific prescription medicine.
